145 related articles for article (PubMed ID: 37685670)
1. Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer.
Sidhu A; Khan N; Phillips C; Briones J; Kapoor A; Zalewski P; Fleshner NE; Chow E; Emmenegger U
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685670
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
3. Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome.
Cheng S; Arciero V; Goldberg H; Tajzler C; Manganaro A; Kozlowski N; Rowbottom L; McDonald R; Chow R; Vasisht G; Shaji S; Wong ECL; Petrovic M; Zhang L; Phillips C; Zalewski P; Kapoor A; Fleshner NE; Chow E; Emmenegger U
Cancer Manag Res; 2019; 11():9307-9319. PubMed ID: 31802949
[TBL] [Abstract][Full Text] [Related]
4. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
[TBL] [Abstract][Full Text] [Related]
5. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
[No Abstract] [Full Text] [Related]
6. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D; Hatakeyama S; Kawaguchi H; Hatayama Y; Ishibashi Y; Kusaka A; Noro D; Tanaka T; Ito H; Okuyama Y; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Aoki M; Ohyama C
Urol Oncol; 2022 Feb; 40(2):64.e1-64.e8. PubMed ID: 34973857
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Ueda Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Clin Genitourin Cancer; 2017 Apr; 15(2):320-325. PubMed ID: 27601278
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
10. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
12. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Hartrampf PE; Bundschuh RA; Weinzierl FX; Serfling SE; Kosmala A; Seitz AK; Kübler H; Buck AK; Essler M; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4727-4735. PubMed ID: 35852555
[TBL] [Abstract][Full Text] [Related]
13. A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
Soares de Pinho I; Esperança-Martins M; Machado B; Dâmaso S; Lopes Brás R; Cantinho G; Fernandes I; Costa L
Cureus; 2024 Feb; 16(2):e53637. PubMed ID: 38449973
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
[TBL] [Abstract][Full Text] [Related]
15. ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.
Schlack K; Krabbe LM; Rahbar K; Isenberg K; Semjonow A; Schrader AJ; Boegemann M
Transl Androl Urol; 2021 Oct; 10(10):3986-3999. PubMed ID: 34804841
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
[TBL] [Abstract][Full Text] [Related]
17. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
[TBL] [Abstract][Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
19. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
20. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
Parimi S; Bondy S; Tsang E; McKenzie MR; Bachand F; Aparicio M; Duncan G; Sunderland K; Olson RA; Pai HH; Alexander AS; LaPointe V; Chi KN; Tyldesley S
Can Urol Assoc J; 2019 Oct; 13(10):E311-E316. PubMed ID: 31364977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]